» Articles » PMID: 29541535

Early Fine Motor Impairment and Behavioral Dysfunction in (Thy-1)-h[A30P] Alpha-synuclein Mice

Overview
Journal Brain Behav
Specialty Psychology
Date 2018 Mar 16
PMID 29541535
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Intraneuronal inclusions of alpha-synuclein are commonly found in the brain of patients with Parkinson's disease and other α-synucleinopathies. The correlation between alpha-synuclein pathology and symptoms has been studied in various animal models. In (Thy-1)-h[A30P] alpha-synuclein transgenic mice, behavioral and motor abnormalities were reported from 12 and 15 months, respectively. The aim of this study was to investigate whether these mice also display symptoms at earlier time points.

Methods: We analyzed gait deficits, locomotion, and behavioral profiles in (Thy-1)-h[A30P] alpha-synuclein and control mice at 2, 8, and 11 months of age. In addition, inflammatory markers, levels of alpha-synuclein oligomers, and tyrosine hydroxylase reactivity were studied.

Results: Already at 2 months of age, transgenic mice displayed fine motor impairments in the challenging beam test that progressively increased up to 11 months of age. At 8 months, transgenic mice showed a decreased general activity with increased risk-taking behavior in the multivariate concentric square field test. Neuropathological analyses of 8- and 11-month-old mice revealed accumulation of oligomeric alpha-synuclein in neuronal cell bodies. In addition, a decreased presence of tyrosine hydroxylase suggests a dysregulation of the dopaminergic system in the transgenic mice, which in turn may explain some of the motor impairments observed in this mouse model.

Conclusions: Taken together, our results show that the (Thy-1)-h[A30P] alpha-synuclein transgenic mouse model displays early Parkinson's disease-related symptoms with a concomitant downregulation of the dopaminergic system. Thus, this should be an appropriate model to study early phenotypes of alpha-synucleinopathies.

Citing Articles

Behavioral analysis of motor and non-motor impairment in rodent models of Parkinson's disease.

Sheta R, Berard M, Musiol D, Martinez-Drudis L, Oueslati A Front Aging Neurosci. 2025; 16:1464706.

PMID: 39763579 PMC: 11701160. DOI: 10.3389/fnagi.2024.1464706.


Application of serum peptidomics for Parkinson's disease in SNCA-A30P mice.

Yin Z, Xu G, Qi Y, Tan D, Chen E, Ding X Heliyon. 2023; 9(12):e21125.

PMID: 38125428 PMC: 10730432. DOI: 10.1016/j.heliyon.2023.e21125.


Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils.

Ekmark-Lewen S, Aniszewska A, Molisak A, Gumucio A, Lindstrom V, Kahle P Aging Brain. 2023; 4:100086.

PMID: 37559953 PMC: 10407822. DOI: 10.1016/j.nbas.2023.100086.


Animal models of Parkinson's disease: bridging the gap between disease hallmarks and research questions.

Dovonou A, Bolduc C, Soto Linan V, Gora C, Peralta Iii M, Levesque M Transl Neurodegener. 2023; 12(1):36.

PMID: 37468944 PMC: 10354932. DOI: 10.1186/s40035-023-00368-8.


miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy.

Xylaki M, Paiva I, Al-Azzani M, Gerhardt E, Jain G, Islam M J Parkinsons Dis. 2023; 13(2):179-196.

PMID: 36744345 PMC: 10041420. DOI: 10.3233/JPD-225055.


References
1.
Fahn S, Libsch L, Cutler R . Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci. 1971; 14(4):427-55. DOI: 10.1016/0022-510x(71)90178-x. View

2.
Spillantini M, Schmidt M, Lee V, Trojanowski J, Jakes R, Goedert M . Alpha-synuclein in Lewy bodies. Nature. 1997; 388(6645):839-40. DOI: 10.1038/42166. View

3.
Kahle P, Neumann M, Ozmen L, Muller V, Jacobsen H, Schindzielorz A . Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci. 2000; 20(17):6365-73. PMC: 6772969. View

4.
Cover T, Blanke S . Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol. 2005; 3(4):320-32. DOI: 10.1038/nrmicro1095. View

5.
Rockenstein E, Mallory M, Hashimoto M, Song D, Shults C, Lang I . Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res. 2002; 68(5):568-78. DOI: 10.1002/jnr.10231. View